This podcast was supported by an unconditional educational grant from Chiesi Farmaceutici S.p.A., who were not involved in its creation or development.
Disclaimer: This podcast discusses prescription-only medicines and is intended for healthcare professionals only. Please refer to prescribing information and adverse event reporting requirements in your country of practice. The views and opinions expressed in this podcast are those of the individual speakers and do not necessarily reflect those of Chiesi Farmaceutici or EMJ.
This podcast explores the important aspects of healthcare professionals’ practices in percutaneous coronary intervention treatment. It includes the role of adjunct therapies, a review of the updated guidelines, and real-world challenges in the treatment and management of acute coronary syndrome. The discussion focuses on expert opinions and real-world experiences, focusing on the current evidence and guidelines surrounding the efficacy and safety of antiplatelet agents, as well as the timing of their administration.
Time stamps:
- 00:00 – Introduction
- 02:25 – Current practices for the management of acute coronary syndrome (ACS)
- 07:06 – The importance of timely intervention for percutaneous coronary intervention (PCI)
- 11:08 – The use of P2Y12 inhibitors in PCI/ACS management
- 15:37 – The evidence behind EU and US guidelines for ACS management
- 24:07 – Best practices in PCI/ACS management
Speakers
Jennifer Rymer1
Alexander Neissner2
1. Associate Professor of Medicine specialising in Cardiology, Duke University School of Medicine; Practicing Interventional Cardiologist, Duke University Hospital, Durham, North Carolina, USA.
2. Professor of Cardiovascular Medicine, Medical University of Vienna; Head of the Cardiology Department, Clinic Landstraße, Vienna, Austria.
